Influenza (seasonal)

Le vaccin contre la grippe aurait des qualités insoupçonnées

Le vaccin contre la grippe, différent chaque année pour suivre la constante évolution du virus, ferait même plus. C'est ce qu'avance une équipe de l'hôpital pour enfants de St Jude à Memphis dans une étude dont les résultats ont été publiés dans la revue web de l'American Society for Microbiology. Des chercheurs qui affirment que ce vaccin saisonnier protégerait également contre d'autres souches de grippe non ciblées par les créateurs du vaccin.

Flu vaccines increase immunity against multiple viruses

Researchers at St. Jude Children’s Research Hospital recently found that seasonal flu vaccines may boost immune systems against multiple flu viruses and not just the viruses in the vaccine.
Scientists at the hospital tested the immune responses of study participants who had received their flu vaccines and found that the participants had a strong immune response against many different types of flu, including the H3N2 flu strain from 2010.

University of Buffalo Develops new transport System for DNA Vaccines for HIV, Malaria, HPV, and Other Major Illnesses

Its performance isn’t measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, influenza and other maladies.
Described recently in the Proceedings of the National Academy of Sciences, the technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses.

CDC's flu warning raises questions about vaccine match

The Centers for Disease Control and Prevention (CDC) warned yesterday that the profile of influenza viruses currently circulating, with A/H3N2 predominant, suggests a risk for a rough ride this winter, especially since about half of the H3N2 viruses don't match up with the corresponding strain in this year's vaccine.

STC to work with Alberta Health to control vaccine inventory

Scientific Technologies Corporation (STC) was recently awarded a contract with Alberta Health to help improve the management process and distribution of vaccine supply.

Hybrid Delivery System Boosts DNA Vaccines Potential

Scientists from the University at Buffalo have created a novel hybrid system designed to deliver genetic antigens and elicit a strong immune response in patients, something DNA vaccines have so far failed to deliver. The hybrid, presented in the Proceedings of the National Academy of Science and described as a “hybrid biosynthetic gene therapy vector development and dual engineering capacity,” brings together two usually distinct technologies to create a hybrid vector: combining a bacterial cell and a synthetic polymer.


Authorities Deem Novartis’ FLUAD Safe

Towards the end of November Italian officials prohibited the use of two batches of Novartis’ flu vaccine FLUAD after 13 deaths were reported to have taken place shortly after vaccination (8 within 24 hours). There were concerns from the AIFA that there may have been quality deficits within the two batches affected (143 301 and 142 701), however they and the ISS have deemed the vaccine safe after a series of negative results from preliminary tests.

Novartis’ Fluad Investigated After 13 Reported Deaths

The Italian medicines agency, AIFA, have suspended the use of two batches of Novartis’ influenza vaccine Fluad after the death of 13 adults, 8 of whom were above the age of 80, between the 7th and 25th of November. The suspension is a precautionary measure undertaken by the AIFA as the majority of the deaths occurred within 24 hours of after receiving the vaccine.

Predicting Flu Evolution the Next Step Towards Better Flu Vaccines

A global team of researchers using a new modelling system have discovered that upon infection, patients exhibit immune responses to every strain that the individual has encountered, not just the infecting strain. The strongest responses came from the strains most closely associated with the infecting strain, but nonetheless a response was recorded to all previously experiences strains. This phenomenon has been dubbed ‘back-boost’ by the researchers.

Early backer of Uber funds smartphone-based device for at-home diagnosis of flu

Shervin Pishevar, one of the earlier backers of new-age taxi service Uber, is throwing his support behind San Diego startup Cue, which is developing a home-enabled diagnostic for testing for testosterone, fertility, inflammation, vitamin D and influenza.